REporting recommendations for tumour MARKer prognostic studies (REMARK)

British Journal of Cancer

Volumn 93, Issue 4, 2005, Pages 387-391

  McShane, L M ^a   Altman, D G ^b   Sauerbrei, W ^c   Taube, S E ^a   Gion, M ^d   Clark, G M ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Ospedale Civile   (Italy)

^e OSI PHARMACEUTICALS INC   (United States)

Author keywords

EORTC; Guidelines; NCI; Prognostic; REMARK; Tumour marker

Indexed keywords

TUMOR MARKER;

BIOINFORMATICS; CANCER RESEARCH; DATA ANALYSIS; HEALTH CARE ORGANIZATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ARTICLE; INFORMATION DISSEMINATION; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM; STANDARD;

BIOMEDICAL RESEARCH; HUMANS; INFORMATION DISSEMINATION; NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 24944452378     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602678     Document Type: Review

References (42)

1. Altman DG (2001a) Systematic reviews of evaluations of prognostic variables. In Systematic Reviews in Health Care. Meta-Analysis in Context Egger M, Davey Smith G, Altman DG (eds) 2nd edn, pp 228-247. London: : BMJ Books
2. Altman DG (2001b) Systematic reviews of evaluations of prognostic variables. BMJ 323: 224-228
3. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518
4. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
5. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
6. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694
7. Bast Jr RC, Ravdin P, Hayes DF, Bates S, Fritsche Jr H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, for the American Society of Clinical Oncology Tumor Markers Expert Panel (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878
8. Biganzoli E, Boracchi P, Marubini E (2003) Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues. Int J Biol Markers 18: 40-48
9. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003a) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49: 1-6
10. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG (2003b) Standards for reporting of diagnostic accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49: 7-18
11. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057
12. Burke HB, Henson DE (1993) Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72: 3131-3135
13. Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91: 4-8
14. Concato J, Feinstein AR, Holford TR (1993) The risk of determining risk with multivariable models. Ann Intern Med 118: 201-210
15. Fielding LP, Fenoglio-Preiser CM, Freedman LS (1992) The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70: 2367-2377
16. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, DiLeo A, Nogaret JM, Hertens D, Verhest A, Larsimont D (2000) Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 113: 675-682
17. Gasparini G (1998) Prognostic variables in node-negative and node-positve breast cancer. Breast Cancer Res Treat 52: 321-331
18. Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219
19. Gion M, Boracchi P, Biganzoli E, Daidone MG (1999) A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers 14: 123-133
20. Hall PA, Going JJ (1999) Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 35: 489-494
21. Hammond ME, Taube SE (2002) Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 29: 213-221
22. Hayes DF, Bast RC, Desch CE, Fritsche Jr H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456-1466
23. Hilsenbeck SG, Clark GM, McGuire WL (1992) Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22: 197-206
24. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA (2002) Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 12: 1-6
25. McGuire WL (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83: 154-155
26. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM, and the National Cancer Institute Bladder Tumor Marker Network (2000) Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 6: 1854-1864
27. McShane LM, Simon R (2001) Statistical methods for the analysis of prognostic factor studies. In Prognostic Factors in Cancer Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch (eds) 2nd edn, pp 37-48. New York: Wiley-Liss
28. Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235: 10-26
29. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D, for the QUOROM Group (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354: 1896-1900
30. Moher D, Schulz KF, Altman D, for the CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285: 1987-1991
31. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N (2002) Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 94: 852-854
32. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536
33. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA (2003a) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88: 1191-1198
34. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ, Lewis IJ (2003b) A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 39: 19-30
35. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10: 4-12
36. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94: 855-857
37. Schilsky RL, Taube SE (2002) Introduction: tumor markers as clinical cancer tests - are we there yet? Semin Oncol 29: 211-212
38. Schumacher M, Holländer N, Schwarzer G, Sauerbrei W (2005) Prognostic factor studies. In Handbook of Statistics in Clinical Oncology Crowley J (ed) pp 307-351. New York: CRC Press (Chapter 18)
39. Simon R (2001) Evaluating prognostic factor studies. In Prognostic Factors in Cancer Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch (eds) 2nd edn, pp 49-56. New York: Wiley-Liss
40. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985
41. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012
42. Thor AD, Liu S, Moore II DH, Edgerton SM (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17: 470-477